PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 23, 2024Journal of Clinical Oncology176 citationsOpen Access

Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study

View Full Paper
ABAditya BardiaIKIan E. KropTKTakahiro Kogawa

Key Points

Key points are not available for this paper at this time.

Abstract

Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate consisting of a humanized antitrophoblast cell-surface antigen 2 (TROP2) monoclonal antibody linked to a potent, exatecan-derived topoisomerase I inhibitor payload via a plasma-stable, selectively cleavable linker.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Bardia et al. (2024) studied this question.

synapsesocial.com/papers/68e6de6eb6db64358765a50ehttps://doi.org/10.1200/jco.23.01909
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1DATOPOTAMAB DERUXTECAN: A BREAKTHROUGH ANTIBODY-DRUG CONJUGATE TRANSFORMING TRIPLE-NEGATIVE BREAST CANCER THERAPY2026
  2. 2DATOPOTAMAB DERUXTECAN: A BREAKTHROUGH ANTIBODY-DRUG CONJUGATE TRANSFORMING TRIPLE-NEGATIVE BREAST CANCER THERAPY2026
  3. 3Preclinical activity of Datopotamab deruxtecan (Dato-DXd), an antibody-drug conjugate targeting TROP2, in poorly differentiated endometrial carcinomas2025 · 3 citations
  4. 4Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast012024 · 174 citations
  5. 5FDA Approval Summary: Datopotamab deruxtecan-dlnk for treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer2025 · 13 citations